

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Olopat OD (Olopatadine Hydrochloride Ophthalmic Solution USP 0.2% w/v)

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Olopatadine Hydrochloride USP

Equivalent to Olopatadine.....0.2% w/v

Benzalkonium Chloride USPNF.....0.01% w/v

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Ophthalmic Solution (Eye drops)

Colourless, clear solution, free from particulate matter.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.

4.2 Posology and method of administration

Posology

The dose is one drop of Olopatadine in the conjunctival sac of the affected eye(s) twice daily (8 hourly). Treatment may be maintained for up to four months, if considered necessary.

Use in elderly

No dosage adjustment in elderly patients is necessary.

Paediatric population

Olopatadine may be used in paediatric patients three years of age and older at the same dose as in adults. The safety and efficacy of Olopatadine in children aged under 3 years has not been established. No data are available.

Use in hepatic and renal impairment

Olopatadine in the form of eye drops has not been studied in patients with renal or hepatic disease. However, no dosage adjustment is expected to be necessary in hepatic or renal impairment (see section 5.2).

Method of administration

For ocular use only.

After the bottle cap is removed, if the tamper evident ring is loose, remove before using the product. To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas, or other surfaces with the dropper tip of the bottle. Keep the bottle tightly closed when not in use.

In case of concomitant therapy with other topical ocular medicines, an interval of five minutes should be allowed between successive applications. Eye ointments should be administered last.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section

6.1.

4.4 Special warnings and precautions for use

Olopatadine is an antiallergic/antihistaminic agent and, although administered topically, is absorbed systemically. If signs of serious reactions or hypersensitivity occur, discontinue the use of this treatment.

Olopatadine eye drops contains benzalkonium chloride which may cause eye irritation.

Benzalkonium chloride has also been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Close monitoring is required with frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised.

Contact lenses

Benzalkonium is known to discolour soft contact lenses. Avoid contact with soft contact lenses. Patients should be instructed to remove contact lenses prior to administration of the eye drop and wait at least 15 minutes after instillation before reinserting contact lenses.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies with other medicinal products have been performed.

In vitro studies have shown that olopatadine did not inhibit metabolic reactions which involve cytochrome P-450 isozymes 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4. These results indicate that olopatadine is unlikely to result in metabolic interactions with other concomitantly administered active substances.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data from the use of ophthalmic olopatadine in pregnant women.

Studies in animals have shown reproductive toxicity following systemic administration (see section 5.3).

Olopatadine is not recommended during pregnancy and in women of childbearing potential not using contraception

Breast-feeding

Available data in animals have shown excretion of olopatadine in milk following oral administration (for details see section 5.3).

A risk to the newborn/infants cannot be excluded. Olopatadine should not be used during breast-feeding.

Fertility

Studies have not been performed to evaluate the effect of topical ocular administration of olopatadine on human fertility.

4.7 Effects on ability to drive and use machines

Olopatadine has no or negligible influence on the ability to drive and use machines.

As with any eye drop, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.

4.8 Undesirable effects

Summary of safety profile

In clinical studies involving 1680 patients, olopatadine eye drops solution was administered one to four times daily in both eyes for up to four months as monotherapy or adjunctive therapy to loratadine 10 mg. Approximately 4.5% of patients can be expected to experience adverse reactions associated with the use of olopatadine eye drops solution; however, only 1.6% of patients discontinued from the clinical studies due to these adverse reactions. No serious ophthalmic or systemic adverse reactions related to olopatadine eye drops solution were reported in clinical studies. The most frequent treatment-related adverse reaction was eye pain, reported at an overall incidence of 0.7%.

Tabulated list of adverse reactions

The following adverse reactions have been reported during clinical studies and postmarketing data and are classified according to the following convention: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$) very rare ($< 1/10,000$) or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

System Organ Classification	Frequency	Adverse Reactions
Immune system disorders	Common	Conjunctivitis
	Known	Hypersensitivity, swelling face

nervous system disorders	common	headache, dysgeusia
	common	fatigue, hypoaesthesia
	known	intolerance
disorders	common	eye pain, eye irritation, dry eye, abnormal sensation in eyes
	common	corneal erosion, corneal epithelium defect, corneal epithelium disorder, contact keratitis, keratitis, corneal burning, eye discharge, photophobia, vision blurred, visual acuity reduced, pharyngospasm, ocular discomfort, eye pruritus, conjunctival follicles, conjunctival disorder, foreign body sensation in eyes, lacrimation increased, erythema of eyelid, eyelid oedema, eyelid disorder, ocular anaemia
	known	corneal oedema, eye oedema, eye itching, conjunctivitis, mydriasis, visual disturbance, eyelid margin stinging
respiratory, thoracic, and mediastinal disorders	common	nasal dryness
	known	rhinorrhoea, sinusitis
gastrointestinal disorders	known	diarrhoea, vomiting,
skin and subcutaneous tissue disorders	common	dermatitis contact, skin burning sensation, dry skin
	known	dermatitis, erythema
general disorders and administration site conditions	common	fatigue
	known	dizziness, malaise

Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.

Reporting of suspected adverse reactions

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects to the National Regulatory Authority

4.9 Overdose

No data are available in humans regarding overdose by accidental or deliberate ingestion. Olopatadine has a low order of acute toxicity in animals.

Prolongation of the QTc interval in dogs was observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.

In the case of overdose, appropriate monitoring and management of the patient should be implemented.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: ophthalmologicals; decongestant and antiallergics; other antiallergics, ATC code: S01GX 09

Olopatadine is a potent selective antiallergic/antihistaminic agent that exerts its effects through multiple distinct mechanisms of action. It antagonises histamine (the primary mediator of allergic response in humans) and prevents histamine induced inflammatory cytokine production by human conjunctival epithelial cells. Data from *in vitro* studies suggest that it may act on human conjunctival mast cells to inhibit the release of pro-inflammatory mediators. In patients with patent nasolacrimal ducts, topical ocular administration of olopatadine eye drops solution was suggested to reduce the nasal signs and symptoms that frequently accompany seasonal allergic conjunctivitis. It does not produce a clinically significant change in pupil diameter.

5.2 Pharmacokinetic properties

Absorption

Olopatadine is absorbed systemically, as are other topically administered medicinal products. However, systemic absorption of topically applied olopatadine is minimal with plasma concentrations ranging from below the assay quantitation limit (<0.5 ng/ml) up to 1.3 ng/ml. These concentrations are 50-to 200-fold lower than those following well tolerated oral doses.

Elimination

From oral pharmacokinetic studies, the half-life of olopatadine in plasma was approximately eight to 12 hours, and elimination was predominantly through renal excretion. Approximately 60-70% of the dose was recovered in the urine as active substance. Two metabolites, the mono-desmethyl and the N- oxide, were detected at low concentrations in the urine.

Since olopatadine is excreted in urine primarily as unchanged active substance, impairment of renal function alters the pharmacokinetics of olopatadine with peak plasma concentrations 2.3-fold greater in patients with severe renal impairment (mean creatinine clearance of 13.0 ml/min) compared to healthy adults. Following a 10 mg oral dose in patients undergoing haemodialysis (with no urinary output), plasma olopatadine concentrations were significantly lower on the haemodialysis day than on the non-haemodialysis day suggesting olopatadine can be removed by haemodialysis.

Studies comparing the pharmacokinetics of 10 mg oral doses of olopatadine in young (mean age 21 years) and elderly (mean age 74 years) showed no significant differences in the plasma concentrations (AUC), protein binding or urinary excretion of unchanged parent drug and metabolites.

A renal impairment study after oral dosing of olopatadine has been performed in patients with severe renal impairment. The results indicate that a somewhat higher plasma concentration can be expected with olopatadine eye drops solution in this population. Since plasma concentrations following topical ocular dosing of olopatadine are 50-to 200-fold lower than after well-tolerated oral doses, dose adjustment is not expected to be necessary in the elderly or in the renally impaired population. Liver metabolism is a minor route of elimination. Dose adjustment is not expected to be necessary with hepatic impairment.

5.3 Preclinical safety data

Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 µL drop size and a 50 kg person, these doses were approximately 150,000 and 50,000 times higher than the maximum recommended ocular human dose (MROHD).

No mutagenic potential was observed when Olopatadine was tested in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of approximately 100,000 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of approximately 15,000 times the MROHD level.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Povidone (P.V.P.K. 30) USP
Disodium Hydrogen Orthophosphate (Dodecahydrate) BP
Sodium Dihydrogen Orthophosphate Dihydrate BP
Sodium Chloride BP
Benzalkonium Chloride USP-NF
Sodium Hydroxide BP
Water for Injections BP

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

36 months from the date of manufacturer

6.4 Special precautions for storage

Store below 25° C. Use the solution within one month after opening of the vial.

6.5 Nature and contents of container

3ml of colourless, clear solution, free from particulate matter filled in 5ml LDPE vial, a carton containing one such vial along with HDPE cap and patient information leaflet.

6.6 Special precautions for disposal

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Marketing Authorization Holder:

Ajanta Pharma Limited

Ajanta House,

Charkop, Kandivli (West),

Mumbai- 400 067,

India

Manufacturing Site Address:

Ciron Drugs & Pharmaceuticals Pvt. Ltd.

N-118, 118/1, 119, 119/1, 119/2, 113 MIDC,

Tarapur, Boisar. Dist: Thane – 401506

Maharashtra State, India.

Ajanta Pharma Ltd.

Mirza - Palashbari Road, Village Kokjhar,

Kamrup (R), Guwahati, Assam-781128, India.

8 MARKETING AUTHORISATION NUMBER(S)

H2016/CTD4106/898

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Feb 16,2017

10 DATE OF REVISION OF THE TEXT

30 July , 2026